TG Therapeutics - TGTX Stock Forecast, Price & News

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TG Therapeutics Trading Down 1.1 %

Shares of TGTX Stock opened at $7.44 on Wednesday. TG Therapeutics has a fifty-two week low of $3.48 and a fifty-two week high of $35.94. The stock's fifty day moving average price is $5.24 and its two-hundred day moving average price is $7.57. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.43 and a current ratio of 4.43. The company has a market cap of $1.07 billion, a PE ratio of -3.04 and a beta of 2.28.

TG Therapeutics (NASDAQ:TGTX - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.04. The business had revenue of $2.02 million for the quarter, compared to analyst estimates of $1.54 million. TG Therapeutics had a negative return on equity of 118.49% and a negative net margin of 4,126.45%. Equities analysts predict that TG Therapeutics will post -2.1 EPS for the current fiscal year.

Analyst Ratings Changes

TGTX has been the subject of a number of recent research reports. Bank of America began coverage on shares of TG Therapeutics in a report on Friday, May 20th. They issued an "underperform" rating for the company. HC Wainwright cut their price target on TG Therapeutics from $68.00 to $19.00 and set a "buy" rating for the company in a research note on Monday, April 18th. StockNews.com upgraded TG Therapeutics to a "sell" rating in a research note on Friday, June 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of TG Therapeutics in a report on Monday, May 9th. Finally, B. Riley dropped their price target on TG Therapeutics from $23.00 to $17.00 and set a "buy" rating for the company in a research note on Monday, June 13th. Three analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, TG Therapeutics has a consensus rating of "Hold" and a consensus price target of $21.25.